Catherine Madigan
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Catherine Madigan
Syndax Pharmaceuticals Inc reported in an 8-K filed December 20, 2024 that Catherine Madigan was terminated as Chief Medical Officer, effective December 20, 2024. The proxy statement of Syndax Pharmaceuticals Inc reports total compensation of $2,643,914 for Catherine Madigan in fiscal 2022, including a base salary of $503,540.
“On December 20, 2024, Syndax Pharmaceuticals, Inc. (the "Company") announced that it has eliminated the Chief Medical Officer position and that Catherine Madigan, M.D. will cease to serve as the Company's Chief Medical Officer and as an employee of the Company effective as of December 20, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Syndax Pharmaceuticals Inc (SNDX)
Proxy statement
Start not stated–2024-12-20
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Syndax Pharmaceuticals Inc (SNDX) | Chief Medical Officer | $503,540 | $2,643,914 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.